This series examines how recent prostate cancer guidelines translate into practice, covering the expansion of radiopharmaceuticals and PARP inhibitors into earlier disease settings, the reorganization of mCRPC therapy by prior treatment exposure, updated patient selection criteria for radium-223, the indispensable role of PSMA PET imaging, and the sequencing questions that remain.
Cutaneous squamous cell carcinoma (CSCC) management is evolving, with updated NCCN guidelines emphasizing more precise risk stratification, deeper biopsies, and earlier integration of systemic immunotherapy, including neoadjuvant and adjuvant PD-1–based therapies. Multidisciplinary care, patient-centered treatment decisions, and emerging research on combination strategies, intralesional therapy, and biomarkers are shaping a new era of personalized, immune-driven CSCC care.
A panelist outlines how advances in molecular diagnostics, particularly NGS, are refining follicular lymphoma classification and informing selective therapeutic decisions—most notably the use of EZH2-targeted therapy. He describes how emerging agents such as CD19-directed therapies, bispecific antibodies, and potent new combinations are reshaping treatment sequencing, which must also account for antigen preservation, prior response durability, and individual patient factors. Together, these updates reflect a rapidly evolving landscape that demands personalized, forward-thinking treatment planning.
